Senators question FDA on work with opioid maker consultant

Several U.S. senators are questioning the Food and Drug Administration’s enactment with a consulting steadfast that helped businesses merchantability medicine painkillers during the nation's overdose crisis.

Democrat Maggie Hassan of New Hampshire and Republican Chuck Grassley of Iowa, among others, person asked the FDA astir imaginable conflicts of involvement successful its enactment with McKinsey and Co.

The senators sent a missive Monday to the FDA noting that the bureau paid McKinsey much than $140 cardinal aft hiring it respective times starting successful 2008.

While helping the government, McKinsey “also worked for a wide scope of actors successful the opioid industry, including galore of the companies that played a pivotal relation successful fueling the opioid epidemic that our state present faces,” the missive said.

Neither the FDA nor McKinsey instantly responded to requests from The Associated Press seeking comment.

Earlier this year, McKinsey agreed to almost $600 cardinal successful settlements with astir each authorities and 5 U.S. territories implicit its enactment with drugmakers connected medicine opioid sales.

Ad

Opioids, which besides see amerciable substances similar heroin, person been linked to astir a fractional cardinal deaths successful the U.S. since 2000, a occupation that has deepened during the COVID-19 pandemic.

Under its contracts with the FDA, McKinsey worked with the Center for Drug Evaluation and Research, the agency's main part for approving medicine opioids and different drugs, the missive states.

While moving with the FDA, McKinsey besides advised opioid manufacturers connected avoiding oversight from the regulator, according to the letter. The advisor advised Purdue Pharma connected however to soften an FDA cause information programme that required companies to pass risks to patients, attraction providers and pharmacists.

The senators noted that the last programme announced successful 2012, “was mostly devoid of the restrictions the FDA had initially proposed.”

The senators asked the FDA to reply respective questions and supply documents by Sept. 15. They privation to cognize however the bureau checks for conflicts of involvement and what its existent narration is with McKinsey.

Ad

They besides asked what disclosures McKinsey made to the bureau astir imaginable conflicts and erstwhile the FDA became alert that McKinsey’s clients included “several large opioid distributors and retailers.”

Four Democratic senators joined Hassan and Grassley successful signing the letter. They see West Virginia’s Joe Manchin, Rhode Island’s Sheldon Whitehouse and Massachusetts Sens. Elizabeth Warren and Edward Markey.

___

Follow Tom Murphy connected Twitter: @thpmurphy

___

The Associated Press Health and Science Department receives enactment from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely liable for each content.

Copyright 2021 The Associated Press. All rights reserved. This worldly whitethorn not beryllium published, broadcast, rewritten oregon redistributed without permission.